 Lyra Therapeutics Inc NASDAQ: LYRA announced the successful outcome of an End-of-Phase 2 EOP2 meeting with the FDA for LYR-210, its lead candidate for the treatment of chronic rhinosinusitis CRS. Lyra and the FDA established key elements of the Phase 3 program. 